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Continuous saline bladder irrigation for two
hours following transurethral resection of
bladder tumors in patients with non-
muscle invasive bladder cancer does not
prevent recurrence or progression
compared with intravesical Mitomycin-C
Andrew T. Lenis1,2,3 , Kian Asanad1, Maher Blaibel4, Nicholas M. Donin1,2,3 and Karim Chamie1,2,3*
Abstract
Background: Intravesical Mitomycin-C (MMC) following transurethral resection of bladder tumor (TURBT), while
efficacious, is associated with side effects and poor utilization. Continuous saline bladder irrigation (CSBI) has been
examined as an alternative. In this study we sought to compare the rates of recurrence and/or progression in
patients with NMIBC who were treated with either MMC or CSBI after TURBT.
Methods: We retrospectively reviewed records of patients with NMIBC at our institution in 2012–2015. Perioperative
use of MMC (40 mg in 20 mL), CSBI (two hours), or neither were recorded. Primary outcome was time to recurrence or
progression. Descriptive statistics, chi-squared analysis, Kaplan-Meier survival analysis, and Cox multivariable regression
analyses were performed.
Results: 205 patients met inclusion criteria. Forty-five (22.0%) patients received CSBI, 71 (34.6%) received MMC, and 89
(43.4%) received no perioperative therapy. On survival analysis, MMC was associated with improved DFS compared
with CSBI (p = 0.001) and no treatment (p = 0.0009). On multivariable analysis, high risk disease was associated with
increased risk of recurrence or progression (HR 2.77, 95% CI: 1.28–6.01), whereas adjuvant therapy (HR 0.35,
95% CI: 0.20–0.59) and MMC (HR 0.43, 95% CI: 0.25–0.75) were associated with decreased risk.
Conclusions: Postoperative MMC was associated with improved DFS compared with CSBI and no treatment.
The DFS benefit seen with CSBI in other studies may be limited to patients receiving prolonged irrigation.
New intravesical agents being evaluated may consider saline as a control given our data demonstrating that
short-term CSBI is not superior to TURBT alone.
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Background
Non-muscle invasive bladder cancer (NMIBC) accounts
for approximately 70% of new cases of urothelial carcin-
oma of the bladder. [1] NMIBC has been considered a
chronic disease due to its high risk of future complica-
tions, including recurrence, which necessitates frequent
monitoring and surveillance. The lifelong risk of recur-
rence and repeated interventions contributes to poor
physician and patient compliance with published guide-
lines, and it significantly burdens the healthcare system
from a financial standpoint. [2, 3] Therefore, strategies
to prevent recurrence and future complications are para-
mount to reducing long-term morbidity and mortality.
The standard adjuvant therapy following transurethral re-
section of bladder tumor (TURBT) for NMIBC is intravesi-
cal instillation of Mitomycin-C (MMC), which has been
shown to decrease rates of recurrence by approximately
11%, although this is variable depending on the number of
and time from prior recurrences. [4, 5] The posited mech-
anism of action is to prevent free-floating tumor cells in the
urine following TURBT from re-implanting onto the blad-
der wall. Although rare, MMC can potentially cause several
significant side effects, including severe lower urinary tract
symptoms, persistent chronic bladder pain, and even blad-
der necrosis in case reports. [6] Furthermore, MMC is con-
traindicated when there is a concern for bladder
perforation and when there is significant post-operative
gross hematuria. Considering these limitations, there is an
urgent need for alternative strategies to prevent the
re-implantation of tumor cells following TURBT, to reduce
recurrence and minimize the morbidity of the disease. A
2012 Cochrane review of intravesical gemcitabine yielded
conflicting results. [7] Apaziquone is a novel intravesical al-
kylating agent that has demonstrated safety and tolerability
in patients as a post-TURBT instillation and is being evalu-
ated in Phase 3 clinical trials (NCT02563561). [8] Alterna-
tively, several groups have utilized sterile water and saline
irrigation over 18–24 h as a strategy to lyse floating tumors
cells and prevent the re-implantation of cells into the blad-
der wall. [9, 10] In our current study, we sought to evaluate
continuous bladder irrigation with isotonic (0.9% NaCl)
normal saline (CBSI) for two hours following TURBT as a
strategy to reduce recurrence or progression in patients
with NMIBC.
Methods
Patient cohort
Patients undergoing endoscopic resection of bladder tu-
mors at our institution between March 2012 and July
2015 were identified from the medical record by Current
Procedure Terminology (CPT)-4 codes for transurethral
biopsy and resection (52204, 52214, 52224, 52234,
52235, 52240). Pathologic and clinical reports were
reviewed, and patients with NMIBC were selected for
inclusion in the cohort. We excluded all patients with
variant histology, including small cell, squamous cell,
adenocarcinoma, lymphepithelioid, sarcomatoid, and
micropapillary disease. We also excluded patients with a
diagnosis of upper tract urothelial carcinoma within one
year, unresectable volume of tumor, known metastatic
disease, less than three months of follow-up, or patients
who underwent cystectomy within three months of diag-
nosis. Patients were categorized based on a modified
AUA Risk Stratification for NMIBC. [11] Low risk was
defined as a solitary LG lesion < 2 cm. Intermediate risk
was defined as any LG T1, solitary LG Ta > 2 cm, mul-
tiple LG Ta, solitary HG Ta < 2 cm, or a history of LG
NMIBC. High risk was defined as any CIS, HG T1, HG
Ta > 2 cm, multiple HG Ta, or any history of HG Ta le-
sions or BCG recurrence. Modification of the AUA risk
groups was made in order to conform to the size criteria
used in the current procedural terminology codes for
TURBT. Follow-up was calculated based on the time of
the last cystoscopy. All study conduct was approved by
the Institutional Review Board at our institution.
Independent variables
All patients received adjuvant CSBI, adjuvant MMC, or
no adjuvant treatment at the discretion of the operating
surgeon. Typically, patients for whom there was a con-
cern for bladder perforation were not given CSBI or
MMC. MMC was given as an instillation of 40 mg in
20 mL of saline. Following a dwell time of 60–90 min,
the MMC was drained from the bladder and the catheter
was left in place if deemed necessary by the surgeon.
CSBI was performed by placement of a three-way Foley
catheter at the conclusion of the case and was left run-
ning for approximately two hours post-operatively. The
rate was kept at maximum flow without titration for this
time. Patients did not require an overnight stay specific-
ally for CSBI.
Dependent variables
Our dependent variable of interest was time to recur-
rence or progression. Recurrence was defined as the
presence of pathologically confirmed urothelial carcin-
oma on biopsy or repeat resection. Patients who were
found to have a lesion visible on cystoscopy that war-
ranted intervention in the office (e.g. fulguration) were
also classified as having disease recurrence. Cytology re-
sults obtained at the time of office fulguration were re-
corded. Progression was defined as any increase in grade
or stage of disease.
Statistical analysis
Comparisons between categorical variables were tested
using Chi-squared analysis and Fisher’s exact test when
appropriate. The two-sample Student’s t-test was used to
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test for differences between continuous variables. Differ-
ences in disease-free survival (DFS) were analyzed using
the Kaplan-Meier method. Cox proportional hazards
models were used to estimate hazards ratios for covari-
ates of interest. All statistical analyses were performed
with Stata statistical software version 14 (StataCorp, Col-
lege Station, TX).
Results
A total of 205 patients underwent TURBT for NMIBC
during the study period and met all inclusion criteria.
Mean age was 71.9 (SD = 11.4) years and 81.5% were
male. Low grade (LG) and high grade (HG) were the pri-
mary grades in 105 (51.2%) and 100 (48.8%) patients, re-
spectively. Stage was Ta without CIS, Ta with CIS, T1
without CIS, T1 with CIS, and CIS alone in 126 (61.5%),
12 (5.9%), 36 (17.6%), 13 (6.3%), and 18 (8.8%) patients,
respectively. Tumor size was < 0.5 cm, 0.5–2 cm, 2–
5 cm, and > 5 cm in 20 (9.8%), 90 (43.9%), 45 (21.9%),
and 50 (24.4%) patients, respectively. Multiple tumors
were present in 105 (51.2%) patients and 75 (36.6%) had
a history of NMIBC. A modified AUA risk stratification
as discussed in the methods resulted in 23 (11.2%) low
risk patients, 80 (39%) intermediate risk patients, and
102 (49.8%) high risk patients. As immediate periopera-
tive therapy, a total of 45 (22.0%) patients had CSBI, 71
(34.6%) had MMC, and 89 (43.4%) had no perioperative
therapy. Only 36 (19.8%) of patients with intermediate
or high risk disease underwent a restaging TURBT.
Eighty-six (42.0%) patients received adjuvant intravesical
therapy, most commonly with bacillus Calmette-Guérin
(BCG n = 76), BCG + interferon (n = 6), Gemcitabine (n
= 2), or MMC (n = 2). Table 1 and Table 2 summarize
the cohort characteristics stratified by perioperative
treatment and recurrence and progression, respectively.
Median follow-up time for the entire cohort was 16
[Interquartile range (IQR): 8–28] months. A total of 74
(36.1%) patients recurred at a median of 9.5 [IQR: 4–14]
months and 16 (7.8%) progressed at a median of 16
[IQR: 6–31.5] months. The median DFS was 25 months
for those who received no perioperative treatment,
55 months for those receiving MMC, and 16 months for
those receiving CSBI. The Kaplan-Meier survival curve
is presented in Fig. 1 and demonstrates a significant DFS
advantage of MMC compared with either CSBI or no
perioperative treatment (log rank test: p < 0.01).
Kaplan-Meier curves for patients with a combination of
low and intermediate risk NMIBC (log rank test: p =
0.02) and high risk NMIBC (log rank test: p = 0.04), and
are presented in Figs. 2 and 3, respectively.
Lastly, we created a multivariable model incorporating
age, AUA risk stratification, use of additional adjuvant
therapy, and type of perioperative therapy (None, MMC,
or CSBI). On Cox multivariable modeling, high risk was
associated with increased risk of recurrence or progres-
sion (HR 2.77, 95% CI: 1.28–6.01), whereas adjuvant
therapy (HR 0.35, 95% CI: 0.20–0.59) and MMC (HR
0.43, 95% CI: 0.25–0.75) were associated with decreased
risk of recurrence or progression (Table 3).
Discussion
The burden of NMIBC includes high financial costs to the
healthcare system, significant risk of recurrence that ne-
cessitates life-long invasive surveillance, and uncertainty
of possible progression that would prompt future radical
operative intervention, especially in the highest-risk pa-
tients. Strategies to reduce the risk of recurrence and pro-
gression, including intravesical chemotherapy and
immunotherapy, have been shown to be effective. [4, 12]
However, none of these are without risk of potential sig-
nificant side effects. In our current study we sought to
utilize postoperative CSBI in a fashion similar to MMC, as
an immediate, one-time postoperative treatment following
surgery. This strategy avoids the toxicity of intravesical
chemotherapy, as well as the inconvenience of an over-
night hospital stay for prolonged CSBI.
In our cohort, however, post-operative CSBI for two
hours was not equivalent to a single dose of periopera-
tive MMC. Given the small numbers of patients in the
low risk subgroup, we combined patients from low risk
and intermediate risk groups for analysis. In the low and
intermediate risk patients, there was a significant im-
provement in DFS with MMC compared with CSBI. In
fact, CSBI performed no better than no perioperative
treatment. In the high risk subgroup, a similar trend was
observed. In our study the absolute risk reduction of
postoperative MMC compared with no treatment at one
year was 12.3%, which is similar to what is reported in
the literature (11.7%). [4, 13] This benefit of MMC holds
true even in our Cox multivariable model.
With respect to the efficacy of CSBI, our data stands in
contrast to results published by others, albeit with some
important differences in study design. Onishi et al. per-
formed a non-randomized study comparing 18–22 h of
post-operative CSBI to a full year of induction and main-
tenance MMC in patients with European Organization for
Research and Treatment of Cancer (EORTC) intermediate
risk NMIBC and showed no difference in several out-
comes, including recurrence-free rates, time to first recur-
rence, and frequency of recurrences. [10] In this
manuscript, the authors alluded to a planned prospective
study that was recently published. [14] In their follow-up
study, 227 patients with primary EORTC low- to
intermediate-risk (all LG) NMIBC were randomized 1:1 to
receive CSBI for 18 h or a single dose of 30 mg of MMC
in 30 mL of saline. After a median follow-up of 37 months,
29% of patients experienced a recurrence. Recurrence-free
rates at 1, 3, and 5 years were similar between the CSBI
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and MMC groups on Kaplan-Meier analysis. Subgroup
analysis showed no difference when stratified between the
low- and intermediate-risk tumors. Adverse events were
also compared and the MMC group was found to have
significantly higher rates of gross hematuria, irritative
bladder symptoms, and dysuria (including retention).
While the equivalence of CSBI and MMC demonstrated
by Onishi et al. could be explained in part by patient selec-
tion (all LG patients), we did not replicate this result even
in the low and intermediate risk subgroups of our cohort.
One important difference in our protocols is the dose of
MMC, which was the standard 40 mg in our study and
30 mg in the study by Onishi et al. The most striking dif-
ference between our studies, however, is in the duration of
CSBI. We intentionally restricted CSBI to two hours to
limit the need for overnight hospital stays. While similarly
efficacious to one instillation of MMC, CSBI used by
Onishi et al. was titrated over 18 h, and it was not re-
ported how many of these patients required an overnight
stay. While the authors debate the cost advantages of sa-
line compared with MMC, we question whether this may
be offset by even a small fraction of patients requiring
overnight admissions for CSBI. Nevertheless, this data
demonstrates that in addition to a standard dose of 40 mg
of MMC, duration may be an important component of
the efficacy of CSBI in preventing tumor cell re-
implantation.
Our results also appear to conflict with the results of a
recent meta-analysis utilizing individual patient data
from randomized trials comparing immediate intravesi-
cal instillation of various chemotherapy agents to
TURBT alone or instillation of control solution (saline
Table 1 Cohort characteristics stratified by perioperative treatment
Variable No treatment MMC CSBI p-value
Total no. of patients 89 71 45 –
Age, mean (SD) 73.2 (11.2) 68.2 (12.3) 75.3 (8.9) < 0.002+
Gender, n (%) 0.54
Male 75 (84.3) 55 (77.5) 37 (83.2)
Female 14 (15.7) 16 (22.5) 8 (17.8)
Grade, n (%) 0.9
High 45 (50.6) 34 (47.9) 21 (46.7)
Low 44 (49.4) 37 (52.1) 24 (53.3)
Stage, n (%) 0.03*
Ta without CIS 55 (61.8) 41 (57.8) 30 (66.7)
Ta with CIS 3 (3.4) 4 (5.6) 5 (11.1)
T1 without CIS 13 (14.6) 18 (25.4) 5 (11.1)
T1 with CIS 4 (4.5) 6 (8.5) 3 (6.7)
CIS only 14 (15.7) 2 (2.8) 2 (4.4)
Tumor size, n (%) 0.12*
< 0.5 cm 11 (12.36) 3 (4.2) 6 (13.3)
0.5–2.0 cm 33 (37.1) 41 (57.8) 16 (35.6)
2.0–5.0 cm 22 (24.7) 13 (18.3) 10 (22.2)
> 5.0 cm 23 (25.8) 14 (19.7) 13 (28.9)
Multiple tumors, n (%) 47 (52.8) 36 (50.7) 22 (48.9) 0.91
Recurrent disease, n (%) 40 (45.0) 23 (32.4) 12 (26.7) 0.08
AUA Risk Stratification 0.72
Low risk 10 (11.2) 6 (8.5) 7 (15.6)
Intermediate risk 34 (38.2) 31 (43.7) 15 (33.3)
High risk 45 (50.6) 34 (47.9) 23 (51.1)
Restaging resection, n (%) 8 (9.0) 18 (25.4) 10 (22.2) 0.02
Adjuvant therapy, n (%) 35 (39.3) 35 (49.3) 16 (35.6) 0.28
Follow-up in months, median [IQR] 14 [6–28] 23 [11–32] 13 [9–19] < 0.01§
MMC Mitomycin-C, CSBI continuous saline bladder irrigation, SD standard deviation, CIS carcinoma in situ. +One-way ANOVA. *Fisher’s exact test. §non-parametric
equality of medians test
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or water). [5] Upon closer examination, however, we are
unable to compare the protocols included as published
in the meta-analysis or in the original manuscripts to
our brief post-operative irrigation protocol. Of the 13 in-
cluded studies, the use of post-operative irrigation was
only documented as consistently used in four of these
studies. Irrigation protocols were not detailed in the
meta-analysis and review of the original data could not
identify specific protocols. Furthermore, at least one
study utilized distilled water for irrigation, which has the
theoretical advantage of an osmotic cytotoxic effect but
the disadvantages of being hypotonic. Therefore, despite
a 21% relative reduction in recurrences found in this
meta-analysis with use of post-operative irrigation alone,
we can only cautiously compare this result with our data
without more detailed information about the irrigation
protocols used.
The concept of utilizing irrigation for eradication of
residual tumor cells following surgery for cancer is not a
new concept, nor is it limited to urology or even endo-
scopic surgery. Surgeons have traditionally irrigated sur-
gical sites to mechanically wash away debris, dilution of
bacterial loads, and as a method of tumor cell lysis, de-
pending on the tonicity of the fluid. A survey in England
found that 74% of general surgeons perform intraopera-
tive peritoneal lavage during cancer operations (36%
Table 2 Cohort characteristics stratified by Recurrence or Progression
Variable Recurrence
or Progression
No Recurrence
or Progression
p-value
Total no. of patients 90 115 –
Age, mean (SD) 73.6 (10.8) 70.6 (11.8) 0.07+
Gender, n (%) 0.81
Male 74 (82.2) 93 (80.9)
Female 16 (17.8) 22 (19.1)
Grade, n (%) 0.38
High 47 (52.2) 53 (46.1)
Low 43 (47.8) 62 (53.9)
Stage, n (%) 0.09*
Ta without CIS 55 (61.1) 71 (61.7)
Ta with CIS 3 (3.3) 9 (7.8)
T1 without CIS 14 (15.6) 22 (19.1)
T1 with CIS 5 (5.6) 8 (7.0)
CIS 13 (14.4) 5 (4.4)
Tumor size, n (%) 0.09
< 0.5 cm 14 (15.6) 6 (5.2)
0.5–2.0 cm 37 (41.1) 53 (46.1)
2.0–5.0 cm 17 (18.9) 28 (24.4)
> 5.0 cm 22 (24.4) 28 (24.3)
Multiplicity of tumor, n (%) 56 (62.2) 49 (42.6) < 0.01
Recurrent disease, n (%) 42 (46.7) 33 (28.7) < 0.01
AUA Risk Stratification 0.07
Low risk 9 (10.0) 14 (12.2)
Intermediate risk 28 (31.1) 52 (45.2)
High risk 53 (58.9) 49 (42.6)
Restaging resection, n (%) 12 (13.3) 24 (20.9) 0.16
Adjuvant therapy, n (%) 32 (35.6) 54 (47.0) 0.10
Perioperative treatment, n (%) 0.004
None 47 (52.2) 42 (36.5)
MMC 20 (22.2) 51 (44.4)
CSBI 23 (25.6) 22 (19.1)
MMC Mitomycin-C, CSBI continuous saline bladder irrigation, SD standard deviation, CIS carcinoma in situ. +One-way ANOVA. *Fisher’s exact test
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with water, 21% with saline, and 17% with betadine). [15]
However, efficacy data on irrigation type is conflicting.
Sweitzer et al. designed an experiment in mice to evalu-
ate whether distilled water or sterile saline irrigation
could reduce the burden of orthotopically implanted
melanoma tumor cells. [16] Unfortunately, they found
that neither the mechanical process of irrigation nor the
hypotonicity of water reduced the tumor burden. In con-
trast, Fumito et al. demonstrated the superiority of water
irrigation to saline irrigation following laparotomy in a
mouse model of colorectal cancer tumor spillage. [17] In
head and neck cancer models, both the type of irrigation
and type of cancer cell line contributed to efficacy. [18, 19]
These and other conflicting data suggest that multiple
Fig. 1 “DFS in Patients with NMIBC”. Kaplan-Meier survival curve for all patients with NMIBC stratified by perioperative treatment. MMC, Mitomycin-C.
CSBI, continuous saline bladder irrigation
Fig. 2 “DFS in Patients with Low and Intermediate Risk”. Kaplan-Meier survival curve for patients with low and intermediate risk disease stratified by
perioperative treatment. MMC, Mitomycin-C. CSBI, continuous saline bladder irrigation
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factors play a role with respect to the eradication of residual
tumor burden, potentially related to the microenvironment
and tumor cell-specific factors, such as cell adhesion prop-
erties and degree of de-differentiation.
The literature does strongly support irrigation follow-
ing intra-luminal surgery in other surgical fields. For ex-
ample, Zhou et al. performed a meta-analysis of studies
evaluating intra-luminal washout following anterior re-
section for rectal cancer and concluded that washout
leads to reduced rates of local recurrence. [20] In the
urologic literature, Moskovitz et al. first postulated in
1987 that intravesical irrigation with distilled water dur-
ing and after TURBT would lead to fewer recurrences.
[21] While several small studies have demonstrated con-
flicting results regarding the use of water irrigation com-
pared with no perioperative treatment, no studies have
compared CSBI to MMC until the aforementioned stud-
ies by Onishi et al. [10, 14, 22, 23] Our study is the first
to compare a shorter, perioperative duration of CSBI to
both MMC and no perioperative treatment, and to
evaluate this strategy in a heterogeneous patient popula-
tion with low, intermediate, and high risk disease.
Fig. 3 “DFS in Patients with High Risk”. Kaplan-Meier survival curve for patients with high risk disease stratified by perioperative treatment. MMC,
Mitomycin-C. CSBI, continuous saline bladder irrigation
Table 3 Cox multivariable model for Recurrence or Progression
Variable Hazard Ratio 95% Confidence
Interval
p-value
Age (per year of age) 1.00 0.98–1.02 0.92
AUA Risk Stratification
Low Risk Reference Reference
Intermediate Risk 0.84 0.39–1.80 0.66
High Risk 2.77 1.28–6.01 0.01
Adjuvant therapy
No Reference Reference
Yes 0.35 0.20–0.59 < 0.001
Perioperative treatment
No perioperative treatment Reference Reference
MMC 0.43 0.25–0.75 0.003
CSBI 0.96 0.58–1.60 0.89
LG low grade, HG high grade, CIS carcinoma in situ, MMC Mitomycin-C, CSBI continuous saline bladder irrigation
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Our results, however, should be considered within the
context of several limitations. Although this was a
hypothesis-based study driven by pre-clinical and clinical
data, it was not a randomized controlled study, and was
limited to the data available in medical records. Further-
more, the study is underpowered and longer term
follow-up is required to fully realize the potential differ-
ences between treatment groups. It is possible that a larger
cohort with longer term follow up could confirm the null
hypothesis, suggesting that no difference exists between
treatment groups. However, at our institution we are mainly
utilizing intravesical gemcitabine based on recently pub-
lished data that suggests efficacy at a fraction of the cost
and with reduced side effects compared with MMC. [24]
Consequently, in combination with the current data that
suggests inefficacy of 2 h of CSBI, we are unlikely to treat
more patients with adjuvant CSBI. Primarily one surgeon
(KC) performed CSBI during the study period while most
other surgeons in the department utilized either MMC or
no additional perioperative therapy. Therefore, referral pat-
terns may have contributed to patient heterogeneity be-
tween groups. Despite some baseline differences between
treatment groups described in our results, the data remains
consistent when controlling for factors such as tumor
grade, stage, and recurrence disease, among others, in a
multivariable model. A consistent surveillance cystoscopy
protocol was not used for all patients and could have
helped standardize follow-up and limit detection bias. Fi-
nally, we utilized a clinical definition of recurrence that in-
cluded any suspicious lesion during office cystoscopy that
warranted an intervention (usually fulguration), which may
have artificially increased our recurrence rates.
Nevertheless, our study comparing perioperative CSBI,
perioperative MMC, and no perioperative treatment an-
swers important questions regarding CSBI as prophy-
laxis following endoscopic resection for NMIBC. While
CSBI for two hours postoperatively should not replace
current guideline-recommended perioperative MMC, it
does appear that longer duration of CSBI may increase
its efficacy. [10, 14] Research is needed to determine
whether the duration can be reduced to limit the num-
ber of additional hospital stays and whether other, novel
perioperative instillations may reduce recurrences and
limit side effects.
Conclusions
Our data demonstrates that perioperative CSBI for two
hours following TURBT is not equivalent to postopera-
tive MMC in terms of rates of recurrence or progres-
sion. CSBI for two hours appears to be equivalent to no
perioperative treatment, regardless of tumor grade. It is
possible that CSBI may be required for a longer duration
to reduce tumor cell re-implantation and, in turn, de-
crease rates of recurrence or progression.
Acknowledgements
This work was supported by the National Institutes of Health Loan Repayment
Program (L30 CA154326 (Principal Investigator: KC)), the STOP Cancer
Foundation (Principal Investigator: KC), the H & H Lee Surgical Resident
Research Award (Recipient: ATL), and the Short Term Training Program (STTP) at
the David Geffen School of Medicine at UCLA (Recipient: KA).
Availability of data and materials
The datasets generated and/or analyzed during the current study are not
publicly available due to patient privacy/protection regulations but may be
available from the corresponding author on reasonable request.
Authors’ contributions
ATL was primarily involved in protocol/project development, data collection/
management, data analysis, manuscript writing/editing. KA was involved in
data collection/management and manuscript writing. MB was involved in
data collection/management and manuscript writing. NMD was involved in
protocol/project development, data collection/management, data analysis,
manuscript writing/editing. KC supervised and was responsible for all study
oversight. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center In-
stitutional Review Board #14–000648.
Consent for publication
Not required given the retrospective nature of this study.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1David Geffen School of Medicine at the University of California Los Angeles,
300 Stein Plaza, Suite 348, Los Angeles, California 90095, USA. 2Department
of Urology, Health Services Research Group, David Geffen School of Medicine
at UCLA, Los Angeles, California, USA. 3Jonsson Comprehensive Cancer
Center, David Geffen School of Medicine at UCLA, Los Angeles, California,
USA. 4Riverside School of Medicine, University of California, Riverside,
California, USA.
Received: 18 October 2017 Accepted: 17 October 2018
References
1. Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, et
al. Bladder cancer J Natl Compr Canc Netw. 2013:446–75.
2. James AC, Gore JL. The costs of non-muscle invasive bladder cancer. Urol.
Clin. North Am. 2013;40:261–9 Available from: http://www.ncbi.nlm.nih.gov/
pubmed/23540783.
3. Chamie K, Saigal CS, Lai J, Hanley JM, Setodji CM, Konety BR, et al.
Compliance with guidelines for patients with bladder cancer: variation in
the delivery of care. Cancer. 2011;117:5392–401 Available from: http://www.
pubmedcentral.nih.gov/articlerender.fcgi?artid=3206145&tool=
pmcentrez&rendertype=abstract.
4. Sylvester RJ, Oosterlinck W, van der Meijden APM. A single immediate
postoperative instillation of chemotherapy decreases the risk of recurrence
in patients with stage ta T1 bladder cancer: a meta-analysis of published
results of randomized clinical trials. J Urol. 2004;171:2186–90 quiz2435.
5. Sylvester RJ, Oosterlinck W, Holmäng S, Sydes MR, Birtle A, Gudjonsson S, et
al. Systematic review and individual patient data meta-analysis of
randomized trials comparing a single immediate instillation of
chemotherapy after transurethral resection with transurethral resection
alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder:
which patients benefit from the instillation? Eur Urol. 2016;69:231–44.
6. Doherty AP, Trendell-Smith N, Stirling R, Rogers H, Bellringer J. Perivesical fat
necrosis after adjuvant intravesical chemotherapy. BJU Int. 1999;83:420–3.
Lenis et al. BMC Urology           (2018) 18:93 Page 8 of 9
7. Jones G, Cleves A, Wilt TJ, Mason M, Kynaston HG, Shelley M. Intravesical
gemcitabine for non-muscle invasive bladder cancer. Cochrane Database
Syst Rev John Wiley & Sons, Ltd. 2012;1:CD009294.
8. Hendricksen K, Cornel EB, de Reijke TM, Arentsen HC, Chawla S, Witjes JA.
Phase 2 study of adjuvant intravesical instillations of apaziquone for high
risk nonmuscle invasive bladder cancer. J Urol. 2012;187:1195–1199.
9. Taoka R, Williams SB, Ho PL, Kamat AM. In-vitro cytocidal effect of water on
bladder cancer cells: the potential role for intraperitoneal lavage during
radical cystectomy. CUAJ. 2015;9:E109–13.
10. Onishi T, Sasaki T, Hoshina A, Yabana T. Continuous saline bladder irrigation
after transurethral resection is a prophylactic treatment choice for non-
muscle invasive bladder tumor. Anticancer Res. 2011;31:1471–4.
11. Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al.
Diagnosis and treatment of non-muscle invasive bladder Cancer: AUA/SUO
guideline. J Urol. 2016;196:1021–9.
12. Sylvester RJ, van der Meijden APM, Lamm DL. Intravesical bacillus Calmette-
Guerin reduces the risk of progression in patients with superficial bladder
cancer: a meta-analysis of the published results of randomized clinical trials.
J Urol. 2002;168:1964–70 Available from: http://www.ncbi.nlm.nih.gov/
pubmed/12394686.
13. Abern MR, Owusu RA, Anderson MR, Rampersaud EN, Inman BA.
Perioperative intravesical chemotherapy in non-muscle-invasive bladder
cancer: a systematic review and meta-analysis. J Natl Compr Cancer Netw.
2013;11:477–84.
14. Onishi T, Sugino Y, Shibahara T, Masui S, Yabana T, Sasaki T Randomized
controlled study of the efficacy and safety of continuous saline bladder
irrigation after transurethral resection for the treatment of n... - PubMed -
NCBI. BJU international. 2016.
15. Whiteside OJH, Tytherleigh MG, Thrush S, Farouk R, Galland RB. Intra-
operative peritoneal lavage--who does it and why? Ann R Coll Surg Engl.
2005;87:255–8.
16. Sweitzer KL, Nathanson SD, Nelson LT, Zachary C. Irrigation does not
dislodge or destroy tumor cells adherent to the tumor bed. J Surg Oncol.
1993;53:184–90.
17. Ito F, Camoriano M, Seshadri M, Evans SS, Kane JM, Skitzki JJ. Water: a
simple solution for tumor spillage. Ann Surg Oncol Springer-Verlag. 2011;18:
2357–63.
18. Lodhia KA, Dale OT, Winter SC. Irrigation solutions in head and neck cancer
surgery: a preclinical efficacy study. Ann Otol Rhinol Laryngol SAGE
Publications. 2015;124:68–71.
19. Hah JH, Roh DH, Jung YH, Kim KH, Sung M-W. Selection of irrigation fluid to
eradicate free cancer cells during head and neck cancer surgery. Head neck.
Wiley subscription services, Inc. A Wiley Company. 2012;34:546–50.
20. Zhou C, Ren Y, Li J, Li X, He J, Liu P. Systematic review and meta-analysis of
rectal washout on risk of local recurrence for cancer. - PubMed - NCBI. J
Surg Res. 2014;189:7–16.
21. Moskovitz B, Levin DR. Intravesical irrigation with distilled water during and
immediately after transurethral resection and later for superficial bladder
cancer. Eur Urol. 1987;13:7–9.
22. Sakai Y, Fujii Y, Hyochi N, Masuda H, Kawakami S, Kobayashi T, et al. A large
amount of distilled water ineffective for prevention of bladder cancer cell
implantation at the time of transurethral resection. Hinyokika Kiyo. 2006;52:173–5.
23. Amos S, Gofrit ON. Prevention of bladder tumor recurrence. Evolving trends
in urology. In: Sashi S Kommu, editor. 1st ed. Rijeka, Croatia: InTech; 2012.
pp. 69–76. https://doi.org/10.5772/38495.
24. Messing EM, Tangen CM, Lerner SP, Sahasrabudhe DM, Koppie TM, Wood
DP, et al. Effect of Intravesical instillation of gemcitabine vs saline
immediately following resection of suspected low-grade non-muscle-
invasive bladder Cancer on tumor recurrence: SWOG S0337 randomized
clinical trial. JAMA. 2018;319:1880–8.
Lenis et al. BMC Urology           (2018) 18:93 Page 9 of 9
